SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts

Transplantation

Volumn 69, Issue 4, 2000, Pages 497-502

  Viklický, Ondrej ^a   Zou, Hequn ^a   Müller, Veronika ^a,b   Lacha, Jiri ^c   Szabó, Attila ^a,b   Heemann, Uwe ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; FIBRONECTIN; INTERCELLULAR ADHESION MOLECULE 1; LAMININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; GLOMERULOSCLEROSIS; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LYMPHOCYTE; MACROPHAGE; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0034055332     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200002270-00006     Document Type: Article

References (49)

1. Cecka JM. Outcome statistics of renal transplants with an emphasis on long-term survival. Clin Transplant 1995; 8: 324.
2. Tilney NL, Whitley WD, Diamond JR, et al. Chronic rejection: an undefined conundrum. Transplantation 1991; 52: 389.
3. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313.
4. Hancock WH, Whitley WD, Tullius SG, et al. Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993; 56: 643.
5. Orosz C. Endothelial activation and chronic allograft rejection. Clin Transplant 1994; 8: 299.
6. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801.
7. Casscells W. Migration of smooth muscle and endothelial cells: critical events in restenosis. Circulation 1992; 86: 723.
8. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660.
9. Cao W, Mohacsi P, Shorthouse R, et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis: inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995; 59: 390.
10. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76: 412.
11. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277.
12. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59: 655.
13. Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989; 17: 609.
14. Wasowska B, Wieder KJ, Hancock WW, et al. Cytokine and alloantibody networks in long term cardiac allografts in rat recipients treated with rapamycin. J Immunol 1996; 156: 395.
15. Schmid C, Heemann U, Azuma H, Tilney NL. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts. Transplantation 1995; 60: 729.
16. Fahrni JA, Berry GJ, Morris RE, Rosen GD. Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model. Transplantation 1997; 63: 533.
17. Reichenspurner H, Soni V, Nitschke M, et al. Obliterative airway disease after heterotopic tracheal xenotransplantation: pathogenesis and prevention using new immunosuppressive agents. Transplantation 1997; 64: 373.
18. Granger DK, Cromwell JW, Chen SC, et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 1995; 59: 183.
19. Kahan BD, Murgia MG, Slaton J, et al. Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Ther Drug Monit 1995; 17: 672.
20. Schuler W, Sedrani R, Cottens S, et al. SDZ-RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.
21. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ-RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997; 64: 32.
22. Diamond JR, Tilney NL, Frye J, et al. Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection. Transplantation 1992; 54: 710.
23. Seeling HP. The Jaffe reaction with creatinine. Reaction product and general reaction conditions. Z Klin Chem Klin Biochem 1969; 7(6): 581.
24. Rennke HS. Pathogenesis and significance of non-primary focal and segmental glomerulosclerosis. Am J Kidney Dis 1989; 13: 443.
25. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
26. Chomczinsky P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Ann Biochem 1987; 162: 156.
27. Siegling A, Lehmann M, Platzer C, et al. A novel multispecific competitor fragment for quantitative PCR analysis of cytokine gene expression in rats. J Immunol Methods 1994; 177: 23.
28. Ando S, Okuda S, Tamaki K, et al. Localization of transforming growth factor-β and latent transforming growth factor-β binding protein in rat kidney. Kidney Int 1995; 47: 733.
29. Feng L, Xia Y, Tang WW, Wilson CB. Cloning a novel form of rat PDGF A-chain with unique 5 [prime]-UT: regulation during development and in glomerulonephritis. Biochem Biophys Res Commun 1993; 194: 1453.
30. Cheng W, Reiss K, Kajstura J, et al. Down-regulation of the IGF-1 system parallels the attenuation in the proliferative capacity of rat ventricular myocytes during postnatal development. Lab Invest 1995; 72: 646.
31. Gao SZ, Schroeder JS, Alderman EL, et al. Prevalence of accelerated coronary artery disease in heart transplant survivals: comparison of cyclosporine and azathioprine regimens. Circulation 1989; 80(pIII): 100.
32. Yousem SA, Burke CM, Billingham ME. Pathological pulmonary alterations in long-term human heart-lung transplantation. Hum Pathol 1985; 16: 911.
33. Ludwig J, Wiesner RH, Batts KP, et al. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987; 7: 476.
34. Mackenzie HS, Tullius SG, Heemann UW, et al. Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest 1994; 94: 2148.
35. Azuma H, Nadeau K, Takada M, et al. Cellular and molecular predictors of chronic renal dysfunction after initial ischemia/ reperfusion injury of a single kidney. Transplantation 1997; 64: 190.
36. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49: 209.
37. cdc2 kinase activation in T lymphocytes. J Biol Chem 1993; 268: 22737.
38. Coito AJ, Binder J, Brown LF, et al. Anti-TNF-α treatment down-regulates the expression of fibronectin and decreases cellular infiltration of cardiac allografts in rats. J Immunol 1995; 154: 2949.
39. Heemann UW, Tullius SG, Tamatami T, Miyasaka M, Milford E, Tilney NL. Infiltration patterns of macrophages and lymphocytes in chronically rejecting rat kidney allografts. Transplant Int 1994; 7: 349.
40. Shihab FD, Tanner AM, Shao Y, Weffer MI. Expression of TGB-β1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996; 50: 1904.
41. Simm A, Nestler M, Hoppe V. PDGF-AA, a potent mitogen for cardiac fibroblasts from adult rats. J Mol Cell Cardiol 1997; 29: 357.
42. Schwartz SM, Heimark RL, Majesky MW. Developmental mechanisms underlying pathology of arteries. Physiol Rev 1990; 70: 1177.
43. Ferns GA, Motani AS, Änggard EE. The insulin-like growth factors: their putative role in atherosclerosis. Artery 1991; 18: 197.
44. Maestri M, Dafoe DC, Adams GA, et al. Insulin-like growth factor-1 ameliorates delayed kidney graft function and the acute nephrotoxic effects of cyclosporine. Transplantation 1997; 64: 185.
45. Häyry P, Myllärniemi M, Aavik E, Loubtschenkov M, Ramirez LC. Role of growth factors in graft vessel disease. Transplant Proc 1997; 29: 2551.
46. von Willebrand E, Jurcic V, Isoniemi H, Häyry P, Paavonen T, Krogerus L. Adhesion molecules and their ligands in chronic rejection of human renal allografts. Transplant Proc 1997; 29: 1530.
47. Koskinen PK, Lemström KB. Adhesion molecule P-selectin and vascular cell adhesion molecule-1 in enhanced heart allograft arteriosclerosis in the rat. Circulation 1997; 95: 191.
48. Tullius SG, Heemann UW, Hancock W, Tilney NL. Long term kidney isografts develop functional and morphological changes which mimic those of chronic allograft rejection. Ann Surg 1994; 220: 425.
49. Nadeau K, Azuma H, Tilney NL. Sequential cytokine expression in renal allografts in rats immunosuppressed with maintenance cyclosporine or mycophenolate mofetil. Transplantation 1996; 62: 1363.